Case Studies: Lipid Emulsion Resuscitation

Lipid emulsion therapies have successfully been used to treat severe and systemic local anesthetic toxicity.

LipidRescue™ & Emulsion Therapies as an Antidote

Combined Spinal Epidural

Patient received a combined spinal epidural (CSE) to undergo cesarean delivery after failing to progress. Patient developed symptoms consistent with local anesthetic systemic toxicity 50-minutes after CSE was administered. Lipid emulsion treatments resolved her symptoms.

Lipid Emulsion to Treat LAST

Infraclavicular Brachial Block

Patient received 30 mL of mepivacaine 1 % and 10 mL of prilocaine 1% and exhibited symptoms consistent with local systemic anesthetic toxicity within 25 minutes. Symptoms of LAST resolved after patient received a 200 mL dose of 20% lipid emulsion.

Lipid Emulsion to Treat LAST

Cardiovascular Collapse

Emergency room patient with a femoral neck fracture received a bupivacaine femoral nerve block. Patient experienced a seizure immediately after receiving the analgesia and was successfully resuscitated using 20% lipid emulsion with no observable side effects.

Lipid Emulsion to Treat LAST

I.V. Lipid Infusion

Patient received brachial block with mepivacaine and bupivacaine and experienced a collapse. After 10-minutes of failed resuscitation attempts, patient received i.v. lipid therapy. The lipid emulsions restored patient’s cardiovascular activity.

Lipid Emulsion to Treat LAST

Epidural Analgesia in a Child

 

Patient with cerebral palsy underwent surgery under epidural analagesia and developed ventricular arrhythmias and decreased cardiac functioning. Patient was resuscitated using adrenaline but hypotension improved only after 20 mL of lipid emulsion waws administered. Thereafter, patient’s cardiac output increased.

Lipid Emulsion to Treat LAST

ResQ Pharma Receives FDA Orphan Drug Designation for LipidRescue™ Therapy for the Treatment of Local Anesthetic Systemic Toxicity

ResQ Pharma Receives FDA’s ODD status for LipidRescue Therapy (LRT) for LAST and on track to file NDA in first half of 2018

Read More

ResQ Pharma’s CEO, Paul Burton to Present at Biotech Showcase

Paul Burton, the CEO of ResQ Pharma, Inc., a biopharmaceutical company focused on commercializing LipidRescue™ Therapy (LRT), which is a treatment for various drug overdoses and poisonings is scheduled to present at Biotech Showcase as part of the J.P. Morgan 35th Annual Healthcare Conference Week in San Francisco.

Read More

ResQ Pharma Raises $725,000

ResQ Pharma, Inc., a biopharmaceutical company focused on commercializing LipidRescue™ Therapy (LRT), which is a treatment for various drug overdoses and poisonings, announces the completion of a second seed-round of equity financing of $725,000.00.

Read More

Guy Weinberg Presents at EAPCCT

ResQ Pharma, Inc., a biopharmaceutical company focused on ensuring reliable, global use of LipidRescue™ Therapy (LRT), a treatment for various lipophilic drug overdoses & poisonings, today announced that Guy Weinberg, M.D., its co-founder and inventor of LRT will be presenting this Friday, May 27th at the Congress Of The European Association Of Poisons Centres And Clinical Toxicologists

Read More